Skip to main content
main-content

The independent medical news service

17-06-2022 | Oncology | News | Article

CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC

The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.

06-06-2022 | Oncology | News | Article

Acetaminophen may blunt ICI response in people with cancer

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

04-06-2022 | Oncology | News | Article

Adjuvant everolimus may benefit RCC patients at high risk for recurrence

Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.

27-04-2022 | Oncology | News | Article

Neurologic AE risk lower with ICIs vs chemotherapy

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

26-04-2022 | Oncology | News | Article

Cabozantinib shows promise for untreated collecting duct RCC

The BONSAI trial has demonstrated encouraging efficacy and manageable toxicity of cabozantinib in treatment-naïve patients with metastatic collecting duct renal cell carcinoma.

22-02-2022 | Oncology | News | Article

​​​​​​​NeoAvAx shows promise of neoadjuvant avelumab–axitinib for localized high-risk RCC

The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.